Oncotype SEQ® Liquid Select is a clinically actionable tumor mutation panel developed with the Community Oncologist in mind
- Intuitive, easy-to-interpret reporting aids rapid understanding of treatment considerations
- Incorporates NCCN® guideline-included genomic alterations with targeted drug associations for solid tumor treatment
- Matches patients to Clinical Trials based on molecular marker enrollment criteria with approximately 90% coverage of currently enrolling Clinical Trials1
The Promise of Liquid Biopsy
Molecular characterization of tumors is now part of standard practice for many solid tumors. Genomic profiling supports treatment decisions based on tumor biology, allowing personalization of care and ensuring that patients get the appropriately targeted therapy. The majority of assays for clinically meaningful molecular alterations have relied on a tissue sample from the tumor. Recent advances requiring smaller amounts of tumor DNA/RNA have enabled the development of assays that are based on blood samples. Next generation sequencing (NGS) technologies have made it possible to sequence minute amounts of DNA, allowing the genomic profiling of circulating cell-free DNA (cfDNA) shed by tumors in the blood stream. Utilizing well-established cancer-specific molecular markers, therapy selection can be personalized based on the patient’s disease.
The Convenience of Liquid Biopsy for Patients
The ability to assess tumor mutation status from circulating cell-free tumor DNA can be a desirable choice for some patients. For example, when a tissue biopsy specimen is unavailable or no longer relevant, or when accessing the tumor for biopsy is not possible because the patient cannot tolerate a surgical procedure or the tumor is in a location that is too risky to reach.
Oncotype SEQ: Targeted Therapy Selection for Solid Tumors with Convenience of Liquid Biopsy
The Oncotype SEQ Liquid Select panel is focused on clinically actionable tumor markers where NCCN® guidelines are available to support clinical intervention. Additionally, it identifies actively enrolling Phase II-IV clinical trials that your patient may be eligible for on the basis of the genomic alterations associated with their disease.